Janux Therapeutics, Inc. (JANX)

Market Cap	778.91M -69.0%
Revenue (ttm)	10.00M -23.4%
Net Income	-101.90M
EPS	-1.68
Shares Out	60.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	195,430
Open	13.15
Previous Close	13.13
Day's Range	12.74 - 13.26
52-Week Range	12.12 - 41.06
Beta	2.87
Analysts	Buy
Price Target	57.36 (+342.93%)
Earnings Date	Feb 26, 2026

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2021
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: JANX
• Website: https://www.januxrx.com

Financial Performance

In 2024, Janux Therapeutics's revenue was $10.59 million, an increase of 30.99% compared to the previous year's $8.08 million. Losses were -$68.99 million, 18.4% more than in 2023.

Analyst Summary

According to 12 analysts, the average rating for JANX stock is "Buy." The 12-month stock price target is $57.36, which is an increase of 342.93% from the latest price.

Price Target

$57.36

(342.93% upside)

Analyst Consensus: Buy